Healthcare Resource Use and Costs of Localized Prostate Cancer Patients in Finland
This study highlights significant cost variations across different treatment pathways for prostate cancer in Finland and underscores the economic impact of metastatic disease. Early detection and effective management are essential for cost containment.
Authors
- Petteri Hervonen
- Mika Pietilä
- Otto Ettala (ORCID: https://orcid.org/0000-0003-1011-4602)
- Timo K. Nykopp (ORCID: https://orcid.org/0000-0002-5857-6040)
- Antti Rannikko (ORCID: https://orcid.org/0000-0002-4261-3484)
- Okko‐Sakari Kääriäinen (ORCID: https://orcid.org/0000-0002-2905-6310)
- Heikki Minn (ORCID: https://orcid.org/0000-0002-5878-4333)
- Teemu J. Murtola (ORCID: https://orcid.org/0000-0003-2932-9590)
- Mari Lahelma (ORCID: https://orcid.org/0000-0002-4845-0196)
- Riikka‐Leena Leskelä (ORCID: https://orcid.org/0000-0002-9255-2958)
- Hanna Ronkainen (ORCID: https://orcid.org/0000-0002-7001-9490)
- Paula Pennanen (ORCID: https://orcid.org/0009-0001-2451-1097)
- T Hakkarainen (ORCID: https://orcid.org/0000-0002-9050-5349)
Institutions
- University of Helsinki (FI)
- Tampere University of Applied Sciences (FI)
- University of Turku (FI)
- Oulu University Hospital (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- Kuopio University Hospital (FI)
- Novo Nordisk (Finland) (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.clgc.2025.102427
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.13